| Walgreens #17488 | |
| 240 Avenue A, Turners Falls, Massachusetts 01376 | |
| (413) 860-3107 |
| Name | Walgreens #17488 |
|---|---|
| Organization Name | Walgreen Co |
| Location | 240 Avenue A, Turners Falls, Massachusetts 01376 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (413) 860-3107 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Most women (85 per cent) would back the idea of more frequent breast screening if they are at higher genetic risk of developing breast cancer, according to research published today by The Breast.
Integra LifeSciences Holdings Corporation announced today the launch of Trel-XPress Demineralized Bone Matrix, expanding its portfolio of bone grafting substitutes for the orthopedic extremity reconstruction surgeon, which includes Integra OS Osteoconductive Scaffold, a synthetic bone void filler manufactured from beta tri-calcium phosphate and type I bovine collagen; Trel-X, a demineralized bone matrix; and Trel-XC, a demineralized bone matrix premixed with cancellous bone.
Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
Helix BioPharma Corp. today announced financial results for the first quarter ended October 31, 2009.
› Verified 8 days ago
| NPI Number | 1154846202 |
| Organization Name | WALGREEN CO |
| Doing Business As | WALGREENS #17488 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 240 Avenue A, Turners Falls, MA 01376 |
| Phone Number | 413-863-3107 |
News Archive
Most women (85 per cent) would back the idea of more frequent breast screening if they are at higher genetic risk of developing breast cancer, according to research published today by The Breast.
Integra LifeSciences Holdings Corporation announced today the launch of Trel-XPress Demineralized Bone Matrix, expanding its portfolio of bone grafting substitutes for the orthopedic extremity reconstruction surgeon, which includes Integra OS Osteoconductive Scaffold, a synthetic bone void filler manufactured from beta tri-calcium phosphate and type I bovine collagen; Trel-X, a demineralized bone matrix; and Trel-XC, a demineralized bone matrix premixed with cancellous bone.
Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
Helix BioPharma Corp. today announced financial results for the first quarter ended October 31, 2009.
› Verified 8 days ago
News Archive
Most women (85 per cent) would back the idea of more frequent breast screening if they are at higher genetic risk of developing breast cancer, according to research published today by The Breast.
Integra LifeSciences Holdings Corporation announced today the launch of Trel-XPress Demineralized Bone Matrix, expanding its portfolio of bone grafting substitutes for the orthopedic extremity reconstruction surgeon, which includes Integra OS Osteoconductive Scaffold, a synthetic bone void filler manufactured from beta tri-calcium phosphate and type I bovine collagen; Trel-X, a demineralized bone matrix; and Trel-XC, a demineralized bone matrix premixed with cancellous bone.
Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
Helix BioPharma Corp. today announced financial results for the first quarter ended October 31, 2009.
› Verified 8 days ago
Kiser's Orthotic & Prosthetic Serv Type: Prosthetic/Orthotic Supplier Location: 7 Burnham St, Turners Falls, Massachusetts 01376 Phone: (413) 772-2573 | |
Walgreens #17488 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 240 Avenue A, Turners Falls, Massachusetts 01376 Phone: (413) 860-3107 |